Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort
Open Access
- 13 May 2024
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-7
Abstract
In chronic lymphocytic leukaemia (CLL), comorbidities assessed by the CLL comorbidity index (CLL-CI) have been associated with outcomes in Western cohorts. We conducted a retrospective analysis of an unselected Middle Eastern cohort of newly diagnosed CLL patients seen at the Kuwait Cancer Control Center (n = 300). Compared to Western studies, these Middle Eastern patients were diagnosed at a younger age (median of 59) and had a higher comorbidity burden (69% non-low risk CLL-CI). A higher CLL-CI score was independently associated with significantly shorter event-free survival and greater risk of death. Our analysis demonstrates that CLL-CI is a valuable tool for comorbidity assessment and prognostic influence in (relatively young) Middle Eastern CLL patients.Keywords
Funding Information
- Kuwait Foundation for the Advancement of Sciences (PR1713MM03)
This publication has 19 references indexed in Scilit:
- TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia casesAmerican Journal of Hematology, 2021
- Metabolic pathways in obesity-related breast cancerNature Reviews Endocrinology, 2021
- Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarifiedWorld Journal of Gastroenterology, 2019
- Untreated Chronic Lymphocytic Leukemia in Lebanese Patients: An Observational Study Using Standard Karyotyping and FISHInternational Journal of Hematologic Oncology, 2017
- Relationship between co‐morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort studyBritish Journal of Haematology, 2017
- Prevalence of type 2 diabetes in the Arab world: impact of GDP and energy consumption.2017
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialThe Lancet Oncology, 2016
- Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemiaBlood, 2014
- Obesity in Gulf CountriesInternational Journal of Health Sciences (Qassim), 2014
- Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemiaLeukemia & Lymphoma, 2008